SCHEMBL1746578

SCHEMBL1746578

OCc1ccc(Oc2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.71
LMNA P02545 1/20 0.63
CYP1A2 P05177 1/20 0.63
PTGS1 P23219 1/20 0.63
SLC6A2 P23975 1/20 0.63
CYP2C19 P33261 1/20 0.63
PTGS2 P35354 1/20 0.63
SLC6A3 Q01959 1/20 0.63
HIF1A Q16665 1/20 0.63
HDAC6 Q9UBN7 1/20 0.63
EPHX2 P34913 1/20 0.62
FFAR1 O14842 3/20 0.59
FFAR4 Q5NUL3 2/20 0.59
MAOB P27338 4/20 0.58
BCHE P06276 1/20 0.58
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
MAOA P21397 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL126452 0.94 LMNA (0.70) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL6192316 0.89 LMNA (0.63) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL5400014 0.88 APP (0.64) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL5538712 0.88 LMNA (0.72) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL891493 0.86 FFAR1 (0.69) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL11849334 0.86 LMNA (0.69) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL23440397 0.86 LMNA (0.59) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL2169314 0.85 LMNA (0.88) LTA4HLMNACYP1A2PTGS1SLC6A2
SCHEMBL1744936 0.84 LTA4H (1.00) LTA4HFFAR1FFAR4MAOAPPARG
SCHEMBL510065 0.84 LTA4H (1.00) LTA4HFFAR1FFAR4MAOAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR LTA4H 1978/4885LMNA 4714/4885CYP1A2 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.